The content of docosahexaenoic acid in serum phospholipid is inversely correlated with plasma homocysteine levels in patients with end-stage renal disease

Nutrition Research

Volumn 30, Issue 8, 2010, Pages 535-540

  Rasmussen, Lars E ^a   Svensson, My ^a   Jørgensen, Kaj A ^b   Schmidt, Erik B ^a   Christensen, Jeppe H ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardiovascular disease; Chronic kidney failure; Homocysteine; Nutrition; Omega 3 fatty acids; Randomized controlled trial

Indexed keywords

DOCOSAHEXAENOIC ACID; HOMOCYSTEINE; OLIVE OIL; OMEGA 3 FATTY ACID; PHOSPHOLIPID; PLACEBO;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FATTY ACID ANALYSIS; HUMAN; KIDNEY FAILURE; LIPID COMPOSITION; MAJOR CLINICAL STUDY; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; CARDIOVASCULAR DISEASES; DIET SURVEYS; DIETARY FATS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PHOSPHOLIPIDS; QUESTIONNAIRES; RENAL DIALYSIS; RISK FACTORS; SEAFOOD; SELF REPORT;

EID: 77956791881     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2010.07.004     Document Type: Article

References (34)

1. Foley R.N., Parfrey P.S., Sarnak M.J. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998, 9(12 Suppl):S16-S23.
2. Longenecker J.C., Coresh J., Powe N.R., Levey A.S., Fink N.E., Martin A., et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002, 13(7):1918-1927.
3. Muntner P., Hamm L.L., Kusek J.W., Chen J., Whelton P.K., He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004, 140(1):9-17.
4. Lewerin C., Ljungman S., Nilsson-Ehle H. Glomerular filtration rate as measured by serum cystatin C is an important determinant of plasma homocysteine and serum methylmalonic acid in the elderly. J Intern Med 2007, 261(1):65-73.
5. Takamitsu Y., Nakanishi T. Association of endothelial dysfunction with sulfur amino acid metabolism in chronic renal failure. Am J Kidney Dis 2001, 38(4 Suppl 1):S95-S99.
6. Mullick A.E., Zaid U.B., Athanassious C.N., Lentz S.R., Rutledge J.C., Symons J.D. Hyperhomocysteinemia increases arterial permeability and stiffness in mice. Am J Physiol Regul Integr Comp Physiol 2006, 291(5):R1349-R1354.
7. Bachmann J., Tepel M., Raidt H., Riezler R., Graefe U., Langer K., et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995, 6(1):121-125.
8. Jamison R.L., Hartigan P., Kaufman J.S., Goldfarb D.S., Warren S.R., Guarino P.D., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007, 298(10):1163-1170.
9. Righetti M. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Clin Chem Lab Med 2007, 45(12):1586-1589.
10. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369(9567):1090-1098.
11. Berstad P., Konstantinova S.V., Refsum H., Nurk E., Vollset S.E., Tell G.S., et al. Dietary fat and plasma total homocysteine concentrations in 2 adult age groups: the Hordaland Homocysteine Study. Am J Clin Nutr 2007, 85(6):1598-1605.
12. Li D., Mann N.J., Sinclair A.J. A significant inverse relationship between concentrations of plasma homocysteine and phospholipid docosahexaenoic acid in healthy male subjects. Lipids 2006, 41(1):85-89.
13. Beavers K.M., Beavers D.P., Bowden R.G., Wilson R.L., Gentile M. Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients. Nephrology (Carlton) 2008, 13(4):284-288.
14. Svensson M., Schmidt E.B., Jorgensen K.A., Christensen J.H. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 2006, 1(4):780-786.
15. Christensen J.H., Skou H.A., Fog L., Hansen V., Vesterlund T., Dyerberg J., et al. Marine n-3 fatty acids, wine intake, and heart rate variability in patients referred for coronary angiography. Circulation 2001, 103(5):651-657.
16. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37(8):911-917.
17. Kaluzny M.A., Duncan L.A., Merritt M.V., Epps D.E. Rapid separation of lipid classes in high yield and purity using bonded phase columns. J Lipid Res 1985, 26(1):135-140.
18. Christoffersen S.W., Glass R.L. Preparation of milk fat methyl esters by alcoholysis in an essentially non-alcholic solution. J Dairy Sci 1969, (52):1289-1290.
19. Altman D.G. Practical statistics for medical research 1991, Chapman and Hall/CRC, London.
20. Li D., Yu X.M., Xie H.B., Zhang Y.H., Wang Q., Zhou X.Q., et al. Platelet phospholipid n-3 PUFA negatively associated with plasma homocysteine in middle-aged and geriatric hyperlipaemia patients. Prostaglandins Leukot Essent Fatty Acids 2007, 76(5):293-297.
21. Fontani G., Corradeschi F., Felici A., Alfatti F., Bugarini R., Fiaschi A.I., et al. Blood profiles, body fat and mood state in healthy subjects on different diets supplemented with omega-3 polyunsaturated fatty acids. Eur J Clin Invest 2005, 35(8):499-507.
22. Mori T.A., Woodman R.J. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 2006, 9(2):95-104.
23. Nygard O., Vollset S.E., Refsum H., Stensvold I., Tverdal A., Nordrehaug J.E., et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995, 274(19):1526-1533.
24. Fiedler R., Mall M., Wand C., Osten B. Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. J Ren Nutr 2005, 15(2):253-256.
25. Holdt B., Korten G., Knippel M., Lehmann J.K., Claus R., Holtz M., et al. Increased serum level of total homocysteine in CAPD patients despite fish oil therapy. Perit Dial Int 1996, 16(Suppl 1):S246-S249. (only abstract published).
26. Olszewski A.J., McCully K.S. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis 1993, 4(1):53-60.
27. Piolot A., Blache D., Boulet L., Fortin L.J., Dubreuil D., Marcoux C., et al. Effect of fish oil on LDL oxidation and plasma homocysteine concentrations in health. J Lab Clin Med 2003, 141(1):41-49.
28. Grundt H., Nilsen D.W., Mansoor M.A., Hetland O., Nordoy A. Reduction in homocysteine by n-3 polyunsaturated fatty acids after 1 year in a randomised double-blind study following an acute myocardial infarction: no effect on endothelial adhesion properties. Pathophysiol Haemost Thromb 2003, 33(2):88-95.
29. Grundt H., Nilsen D.W., Hetland O., Mansoor M.A. Clinical outcome and atherothrombogenic risk profile after prolonged wash-out following long-term treatment with high doses of n-3 PUFAs in patients with an acute myocardial infarction. Clin Nutr 2004, 23(4):491-500.
30. Diakoumopoulou E., Tentolouris N., Kirlaki E., Perrea D., Kitsou E., Psallas M., et al. Plasma homocysteine levels in patients with type 2 diabetes in a Mediterranean population: relation with nutritional and other factors. Nutr Metab Cardiovasc Dis 2005, 15(2):109-117.
31. Chen Z., Banerjee R. Purification of soluble cytochrome b5 as a component of the reductive activation of porcine methionine synthase. J Biol Chem 1998, 273(40):26248-26255.
32. Mori T.A., Woodman R.J., Burke V., Puddey I.B., Croft K.D., Beilin L.J. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 2003, 35(7):772-781.
33. Grundt H., Nilsen D.W., Mansoor M.A., Nordoy A. Increased lipid peroxidation during long-term intervention with high doses of n-3 fatty acids (PUFAs) following an acute myocardial infarction. Eur J Clin Nutr 2003, 57(6):793-800.
34. Wu W.H., Lu S.C., Wang T.F., Jou H.J., Wang T.A. Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women. Eur J Clin Nutr 2006, 60(3):386-392.